Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan

Abstract

Despite numerous advances in treatment options, advanced gastric cancer (AGC) remains a major public health issue and the leading cause of cancer-related deaths. Cisplatin is one of the most effective broad-spectrum anticancer drugs for AGC and a doublet combination regimen of either cisplatin-based or 5-fluorouracil (5FU)-based chemotherapy is generally used for treatment of patients with AGC. However, there is still no consensus on the best regimen for treating AGC. Recently, various new chemotherapeutic agents, including oral 5FU, taxanes, and irinotecan, have been identified as improving the outcomes for AGC when used as a single agent or in combination with non-platinum chemotherapy. Nonetheless, it is still unclear whether non-platinum-based chemotherapy is a viable treatment option for patients with AGC. Accordingly, this review focuses on the efficacy and tolerability of non-platinum-based chemotherapy for patients with AGC.

Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis

“…Fluorouracil (Fu)-based chemotherapy has been widely used as chemotherapy for gastric cancer (12). Large clinical studies of REAL-2 and ML17032 demonstrated the value of oral Fu drugs, including capecitabine, as a first-line treatment…”

Elevated Neutrophil–to–Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy

“…The current standard practice for treating advanced gastric cancer (AGC) is a doublet combination regimen of either platinum-based or 5-fluorouracil (5FU)based chemotherapy (1). Also, various new chemotherapeutic agents, including oral 5FU, irinotecan, and taxanes, have been identified to improve the outcomes for AGC (2). A recent targeted-agent trial showed that the addition of trastuzumab to conventional chemotherapy significantly improved the survival of patients with human epidermal receptor 2 (HER2)-positive AGC (3).…”

Multidrug resistance gene expression response to cisplatin and 5FU treatment in hepatoma, prostate and colon cancer cells

“…Cisplatin was one of the first chemotherapeutic agents employed for many human cancers and keeping its popularity as the most widely used anticancer agent. Doublet therapy with platinum drugs, generally cisplatin in combination with either infused 5FU or an oral 5FU, is current standard application in many countries [12,13]. The aim of the current study was to investigate the cytotoxic effects of cisplatin and 5FU in mainly hepatoma cell model, Hep3B and other cell lines namely human colorectal adenocarcinoma cell line HT29 and human prostate cancer cell line PC3.…”